Zealand Pharma AS (CHIX:ZEALC) Pre-Tax Income : kr-716.6 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Zealand Pharma AS Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Zealand Pharma AS's pretax income for the three months ended in Jun. 2024 was kr-294.1 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was kr-716.6 Mil. Zealand Pharma AS's pretax margin was -861.59%.

During the past 13 years, Zealand Pharma AS's highest Pretax Margin was 1645.87%. The lowest was -1395.20%. And the median was -206.06%.

Zealand Pharma AS Pre-Tax Income Historical Data

The historical data trend for Zealand Pharma AS's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Pre-Tax Income Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-576.68

-673.53

-758.89

-972.04

-708.87

Zealand Pharma AS Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Pre-Tax Income	Get a 7-Day Free Trial															-321.05	72.83	-265.32	-230.00	-294.07

Competitive Comparison of Zealand Pharma AS's Pre-Tax Income

For the Biotechnology subindustry, Zealand Pharma AS's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Pre-Tax Income falls into.

Zealand Pharma AS Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Zealand Pharma AS's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-577.217	+	0	+	-24.888	+	45.324	+	-152.084
	=	-708.9

Zealand Pharma AS's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-267.678	+	0	+	-57.542	+	31.152	+	5.6843418860808E-14
	=	-294.1

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-716.6 Mil.

Zealand Pharma AS (CHIX:ZEALc) Pre-Tax Income Explanation

Zealand Pharma AS's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-294.068	/	34.131
	=	-861.59%

During the past 13 years, Zealand Pharma AS's highest Pretax Margin was 1645.87%. The lowest was -1395.20%. And the median was -206.06%.

Zealand Pharma AS Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (CHIX:ZEALc) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA 0NZU:UK ZEAL:Denmark 22Z:Germany 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines